{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:47:48Z","timestamp":1783770468841,"version":"3.55.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.prro.2025.03.006","type":"journal-article","created":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T19:41:35Z","timestamp":1743968495000},"page":"428-450","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Quality and Safety Considerations for Radiopharmaceutical Therapy in the Radiation Oncology Environment: An ASTRO Safety White Paper"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1106-5224","authenticated-orcid":false,"given":"Jacqueline E.","family":"Zoberi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef","family":"Charara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Clements","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freddy E.","family":"Escorcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"St. James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipose G.","family":"Mulugeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiv","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.prro.2025.03.006_bib0001","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s00259-022-05785-x","article-title":"Joint EANM, SNMMI and IAEA enabling guide: How to set up a theranostics centre","volume":"49","author":"Herrmann","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2025.03.006_bib0002","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ijrobp.2020.11.048","article-title":"A framework for patient-centered pathways of care for radiopharmaceutical therapy: An ASTRO consensus document","volume":"109","author":"Buatti","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.006_bib0003","unstructured":"United States Nuclear Regulatory Commission. Part 35\u2014Medical use of byproduct material. NRC, 10 CFR. 2020. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/index.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0004","doi-asserted-by":"crossref","first-page":"816","DOI":"10.2967\/jnumed.120.252494","article-title":"A rapid and safe infusion protocol for 177Lu peptide receptor radionuclide therapy","volume":"62","author":"Ebbers","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/COC.0000000000001072","article-title":"ACR-ACNM-ARS-ASTRO-SNMMI practice parameter for the performance of therapy with radiopharmaceuticals","volume":"47","author":"Wallner","year":"2024","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.prro.2025.03.006_bib0006","unstructured":"United States Nuclear Regulatory Commission. Procedures for administrations requiring a written directive. NRC, 10 CFR. 35.41. 2018. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-0041.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0007","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2967\/jnmt.120.243378","article-title":"USP General Chapter <825>Impact on Nuclear Medicine Technology Practice","volume":"48","author":"Hinkle","year":"2020","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.prro.2025.03.006_bib0008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.icrp.2011.01.002","article-title":"ICRP Publication 113. Education and training in radiological protection for diagnostic and interventional procedures","volume":"39","author":"Va\u00f1\u00f3","year":"2009","journal-title":"Ann ICRP"},{"key":"10.1016\/j.prro.2025.03.006_bib0009","unstructured":"American College of Radiology, American Association of Physicists in Medicine, American College of Nuclear Medicine, Society of Nuclear Medicine and Molecular Imaging, Society for Pediatric Radiology. ACR\u2013AAPM\u2013ACNM\u2013SNMMI\u2013SPR Technical Standard for Therapeutic Procedures Using Radiopharmaceuticals. 2022. Accessed April 29, 2025. https:\/\/gravitas.acr.org\/PPTS\/DownloadPreviewDocument?ReleaseId=2&DocId=153"},{"key":"10.1016\/j.prro.2025.03.006_bib0010","unstructured":"American Association of Physicists in Medicine. Definition of A qualified medical physicist. 2018. Accessed April 29, 2025. https:\/\/w3.aapm.org\/medical_physicist\/fields.php"},{"key":"10.1016\/j.prro.2025.03.006_bib0011","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/acm2.12469","article-title":"AAPM medical physics practice guideline 10.a.: Scope of practice for clinical medical physics","volume":"19","author":"Clements","year":"2018","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.prro.2025.03.006_bib0012","unstructured":"American Association of Physicists in Medicine. Report No. 249 - Essentials and Guidelines for Clinical Medical Physics Residency Training Programs. 2013. Accessed April 29, 2025. https:\/\/aapm.org\/pubs\/reports\/detail.asp?docid=149"},{"key":"10.1016\/j.prro.2025.03.006_bib0013","unstructured":"American Association of Physicists in Medicine. PET\/CT Acceptance Testing and Quality Assurance. The Report of AAPM Task Group 126. 2019. Accessed April 29, 2025. https:\/\/www.aapm.org\/pubs\/reports\/RPT_126.pdf"},{"key":"10.1016\/j.prro.2025.03.006_bib0014","unstructured":"United States Nuclear Regulatory Commission. Part 19\u2014Notices, instructions and reports to workers: inspection and investigations. NRC, 10 CFR. 2020. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part019\/full-text.html"},{"issue":"3 Suppl","key":"10.1016\/j.prro.2025.03.006_bib0015","doi-asserted-by":"crossref","first-page":"E524","DOI":"10.1016\/j.ijrobp.2021.07.1433","article-title":"Embracing inpatient radiopharmaceutical therapies in radiation oncology: An example with commissioning pediatric I-131 MIBG therapy","volume":"111","author":"Maughan","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.03.006_bib0016","unstructured":"United States Nuclear Regulatory Commission. Part 20\u2014Standards for protection against radiation. NRC, 10 CFR. 2023. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part020\/full-text.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0017","unstructured":"United States Nuclear Regulatory Commission. Written directives. NRC, 10 CFR. 35.40. 2018. Accessed Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-0040.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0018","unstructured":"United States Nuclear Regulatory Commission. Consolidated guidance about materials licenses, program-specific guidance about medical use licenses, Final Report (NUREG-1556, Volume 9, Revision 3). Appendix U. 2019. Accessed April 29, 2025. https:\/\/www.nrc.gov\/docs\/ML1925\/ML19256C219.pdf"},{"key":"10.1016\/j.prro.2025.03.006_bib0019","unstructured":"National Council on Radiation Protection and Measurements. NCRP 49: Structural shielding design and evaluation for medical use of X-rays and gamma-rays of energies up to 10MeV. 42 CFR 37.43. 1976. Accessed April 29, 2025. https:\/\/law.resource.org\/pub\/us\/cfr\/ibr\/005\/ncrp.49.1976.pdf"},{"key":"10.1016\/j.prro.2025.03.006_bib0020","unstructured":"National Council on Radiation Protection and Measurements. Report No. 147 \u2013 Structural shielding design for medical X-ray imaging facilities. 2004. Accessed April 29, 2025. https:\/\/ncrponline.org\/shop\/reports\/report-no-147-structural-shielding-design-for-medical-x-ray-imaging-facilities-2004\/"},{"key":"10.1016\/j.prro.2025.03.006_bib0021","article-title":"Recommended irrigation volume for an intravenous port: Ex vivo simulation study","volume":"13","author":"Wu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.prro.2025.03.006_bib0022","doi-asserted-by":"crossref","first-page":"937","DOI":"10.2967\/jnumed.118.230607","article-title":"NANETS\/SNMMI procedure standard for somatostatin receptor\u2013based peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"60","author":"Hope","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13550-020-00618-0","article-title":"Added value of 68Ga-PSMA PET\/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy","volume":"10","author":"Zacho","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.prro.2025.03.006_bib0024","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13550-020-00658-6","article-title":"Extravasation of [177Lu]Lu-DOTATOC: Case report and discussion","volume":"10","author":"Arveschoug","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.prro.2025.03.006_bib0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s40658-021-00378-3","article-title":"Tissue dose estimation after extravasation of 177Lu-DOTATATE","volume":"8","author":"Tylski","year":"2021","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.prro.2025.03.006_bib0026","unstructured":"United States Nuclear Regulatory Commission. Rulemaking: Reporting nuclear medicine injection extravasations as medical events. 10 CFR Part 35. 2022. Accessed April 29, 2025. https:\/\/www.nrc.gov\/materials\/miau\/med-use-toolkit\/reporting-nuclear-medicine-injection-extravasations.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0027","unstructured":"United States Nuclear Regulatory Commission. Subpart M\u2014Reports. Report and notification of a medical event. 10 CFR 35.3045. 2020. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-3045.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0028","unstructured":"United States Nuclear Regulatory Commission. Decay-in-storage. NRC, 10 CFR 35.92. 2007. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-0092.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0029","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s13139-014-0315-z","article-title":"Production of 177Lu for targeted radionuclide therapy: Available options","volume":"49","author":"Dash","year":"2015","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.prro.2025.03.006_bib0030","unstructured":"United States Nuclear Regulatory Commission. Transfer of byproduct material. NRC, 10 CFR 30.41(b). 1978. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part030\/part030-0041.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0031","unstructured":"United States Nuclear Regulatory Commission. Transfer for disposal and manifests. NRC, 10 CFR 20.2006. 2021. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part020\/part020-2006.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0032","unstructured":"United States Nuclear Regulatory Commission. Disposal of certain byproduct material. NRC, 10 CFR 20.2008. 2021. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part020\/part020-2008.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0033","unstructured":"United States Nuclear Regulatory Commission. Disposal by release into sanitary sewerage. NRC, 10 CFR 20.2003. 2021. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part020\/part020-2003.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0034","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.2967\/jnumed.123.265750","article-title":"Radiation safety considerations of household waste disposal after release of patients who have received [177Lu]Lu-PSMA-617","volume":"64","author":"Graves","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0035","unstructured":"United States Nuclear Regulatory Commission. Release of individuals containing unsealed byproduct material or implants containing byproduct material. NRC, 10 CFR 35.75. 2007. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-0075.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0036","unstructured":"United States Nuclear Regulatory Commission. Consolidated guidance about materials licenses: Program-specific guidance about medical use licenses: Appendix U. Final Report (NUREG-1556, Volume 9, Revision 3). Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/nuregs\/staff\/sr1556\/v9\/index.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0037","unstructured":"Federal Register. Nuclear Regulatory Commission. Draft regulatory guide: Release of patients administered radioactive material. 10 CFR 35. 2023. Accessed April 29, 2025. https:\/\/www.govinfo.gov\/content\/pkg\/FR-2023-04-21\/pdf\/2023-08418.pdf"},{"key":"10.1016\/j.prro.2025.03.006_bib0038","first-page":"34N","article-title":"NRC. NUREG-1556 volume 9 workshop","volume":"43","author":"Uffelman","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0039","unstructured":"U.S. Nuclear Regulatory Commission. Release of patients administered radioactive material. Regulatory Guide 8.39 Revision 1. 2020. Accessed April 29, 2025. https:\/\/www.nrc.gov\/docs\/ML1923\/ML19232A081.pdf"},{"key":"10.1016\/j.prro.2025.03.006_bib0040","unstructured":"United States Nuclear Regulatory Commission. Subpart B\u2014General administrative requirements. NRC, 10 CFR Part 35. 2018. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/index.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0041","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12199-019-0769-9","article-title":"Occupational exposure to blood and body fluids and associated factors among health care workers at the University of Gondar Hospital, Northwest, Ethiopia","volume":"24","author":"Yasin","year":"2019","journal-title":"Environ Health Prev Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0042","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.prro.2023.12.014","article-title":"Handling patient emergencies during radiopharmaceutical therapy","volume":"14","author":"Maughan","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.03.006_bib0043","unstructured":"United States Nuclear Regulatory Commission. Procedures for administrations requiring a written directive. NRC 10, CFR 35.41. 2019. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-0041.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0044","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2967\/jnmt.122.263814","article-title":"177Lu-PSMA Therapy","volume":"50","author":"Parent","year":"2022","journal-title":"J Nucl Med Technol"},{"key":"10.1016\/j.prro.2025.03.006_bib0045","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2967\/jnumed.119.240911","article-title":"NANETS\/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy","volume":"61","author":"Hope","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0046","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.13899","article-title":"Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in lutetium-177 prostate-specific membrane antigen (PSMA) therapy","volume":"24","author":"Zoberi","year":"2023","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.prro.2025.03.006_bib0047","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/RLU.0000000000004182","article-title":"ACR-ACNM-ASTRO-SNMMI practice parameter for lutetium-177 (Lu-177) DOTATATE therapy","volume":"47","author":"Love","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0048","unstructured":"United States Nuclear Regulatory Commission. Records of surveys for ambient radiation exposure rate. NRC, 10 CFR 35.2070. 2017. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-2070.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0049","unstructured":"United States Nuclear Regulatory Commission. Records of the release of individuals containing unsealed byproduct material or implants containing byproduct material. NRC, 10 CFR 35.2075. 2017. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-2075.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0050","unstructured":"United States Nuclear Regulatory Commission. Determination of dosages of unsealed byproduct material for medical use. NRC, 10 CFR 35.63. 2007. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part035\/part035-0063.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0051","series-title":"The Checklist Manifesto: How to Get Things Right","author":"Gawande","year":"2009"},{"key":"10.1016\/j.prro.2025.03.006_bib0052","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.prro.2017.01.015","article-title":"Improving patient safety and workflow efficiency with standardized pretreatment radiation therapist chart reviews","volume":"7","author":"Younge","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.03.006_bib0053","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/j.ijrobp.2008.06.464","article-title":"Improving safety for patients receiving radiotherapy: The successful application of quality assurance initiatives","volume":"72","author":"Marks","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.prro.2025.03.006_bib0054","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.2967\/jnumed.107.050203","article-title":"Routine quality control of clinical nuclear medicine instrumentation: a brief review","volume":"49","author":"Zanzonico","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0055","unstructured":"American Association of Physicists in Medicine. The selection, use, calibration, and quality assurance of radionuclide calibrators used in nuclear medicine. Report of AAPM Task Group 181. 2012. Accessed April 29, 2025. https:\/\/www.aapm.org\/pubs\/reports\/RPT_181.pdf"},{"key":"10.1016\/j.prro.2025.03.006_bib0056","unstructured":"United States Nuclear Regulatory Commission. Subpart F\u2014Surveys and monitoring. NRC, 10 CFR 20.1501. 2011. Accessed April 29, 2025. https:\/\/www.nrc.gov\/reading-rm\/doc-collections\/cfr\/part020\/part020-1501.html"},{"key":"10.1016\/j.prro.2025.03.006_bib0057","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.brachy.2020.07.004","article-title":"Initial experience and lessons learned with implementing lutetium-177-dotatate radiopharmaceutical therapy in a radiation oncology-based program","volume":"20","author":"Maughan","year":"2021","journal-title":"Brachytherapy"},{"issue":"Suppl 3","key":"10.1016\/j.prro.2025.03.006_bib0058","doi-asserted-by":"crossref","first-page":"36S","DOI":"10.2967\/jnumed.121.262748","article-title":"An international study of factors affecting variability of dosimetry calculations, Part 1: Design and early results of the SNMMI dosimetry challenge","volume":"62","author":"Uribe","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0059","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2967\/jnumed.122.265094","article-title":"An international study of factors affecting variability of dosimetry calculations, Part 2: Overall variabilities in absorbed dose","volume":"64","author":"Brosch-Lenz","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0060","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2967\/jnumed.108.056036","article-title":"MIRD pamphlet No. 21: A generalized schema for radiopharmaceutical dosimetry\u2014Standardization of nomenclature","volume":"50","author":"Bolch","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0061","first-page":"37S","article-title":"MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0062","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.2967\/jnumed.111.100123","article-title":"MIRD pamphlet No. 23: Quantitative SPECT for patient-specific 3-dimensional dosimetry in internal radionuclide therapy","volume":"53","author":"Dewaraja","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0063","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.semradonc.2020.07.008","article-title":"Dosimetry for optimized, personalized radiopharmaceutical therapy","volume":"31","author":"Graves","year":"2021","journal-title":"Semin Radiat Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.prro.2025.03.006_bib0064","doi-asserted-by":"crossref","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62","author":"Wahl","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2025.03.006_bib0065","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1200\/JCO.23.01241","article-title":"How can radiopharmaceutical therapies reach their full potential? Improving dose reporting and phase I clinical trial design","volume":"42","author":"Kiess","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.03.006_bib0066","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2022.03.018","article-title":"ASTRO\u2019s framework for radiopharmaceutical therapy curriculum development for trainees","volume":"113","author":"Kiess","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025000712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025000712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:41:31Z","timestamp":1756456891000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025000712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":66,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1879850025000712"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.03.006","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality and Safety Considerations for Radiopharmaceutical Therapy in the Radiation Oncology Environment: An ASTRO Safety White Paper","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}